ZTS|Analyst Targets
ZTS|Company Info
ZTS|Insider Trading
ZTS|Fundamentals
ZTS|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.51 | - | - |
| Q2'26 | $1.87 | $1.87 | -0.2% |
| Q1'26 | $1.62 | $1.53 | -5.3% |
| Q4'25 | $1.62 | $1.48 | -8.4% |
| Q3'25 | $1.62 | $1.70 | +4.8% |
| Q2'25 | $1.61 | $1.76 | +9.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.3B | - | - |
| Q2'26 | $2.5B | $2.5B | -2.3% |
| Q1'26 | $2.3B | $2.3B | -2.8% |
| Q4'25 | $2.3B | $2.4B | +3.1% |
| Q3'25 | - | $2.4B | - |
| Q2'25 | - | $2.5B | - |
ZTS|Monthly Returns
Market Data
ZTS Stock Snapshot
- Market cap
- 30.89B
- P/E ratio
- 11.8
- Day range
- $74.25 – $75.90
- News sentiment
- 50/100 · Neutral
- Analyst target
- $94.86 (+26.1%)
- Consensus
- Hold · 26 analysts
Price action on ZTS is defensive - rallies are being sold rather than extended. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Behaviour On Record
What ZTS's own history says about today's numbers
- Realized volatility (21d)
- 21.0% 42nd pct
- Below its peak
- -69.9%
- vs 200-day average
- -23.2%
- Up days (1y)
- 46%
Zoetis Inc. is currently running 21.0% annualised volatility over the last 21 sessions. Measured against ZTS's own 13 years of daily returns rather than a market-wide average, that is the 42nd percentile — close to its own typical level, against a typical reading of 22.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ZTS is trading -69.9% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -19.6%, and the deepest was -43.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -23.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 4th percentile — a narrower gap than it typically runs. Over the past year ZTS closed higher on 46% of sessions, and it is currently 2 sessions into a falling streak.
On October specifically: over 14 years of records, ZTS finished the month higher 5 of 14 times, with a median return of -1.5% and an average of -0.8%. Its strongest month historically has been July at +3.7% on average, its weakest March at -2.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ZTS has opened more than 2% away from the prior close in 79 of 3,268 sessions (2.4% of the time), with the largest gaps running +7.7% and -6.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, ZTS moved an average of 4.3% in the session after earnings, closing higher 1 of those 3 times, with a median move of -5.6% and a largest of -6.2%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ZTS's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ZTS's sector?
Zoetis Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on ZTS?
TD Cowen most recently reiterated its rating on Zoetis Inc. to Buy on Aug 25, 2026 with a price target of $94 (from $104). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- TD Cowen — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
Earnings Release, Scored
What did Zoetis Inc.'s latest earnings release say?
Most important lines
- 1
Revises Full Year 2026 Revenue Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)%
Guidance lowered - 2
Revises Full Year 2026 Adjusted Net Income Guidance to Organic Operational Growth of (9)% to (5)%
Guidance loweredNew this quarter - 3
The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational 1 basis.
Negative tone
Peers & ETF holders
ZTS peers & ETF holders
Drug Manufacturers - Specialty & GenericMarket cap · today
- ZTSYou're here$30.9B-0.13%
- VTRSViatris Inc.$19.9B-0.06%
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 47,780,974 | 11.49% | $6.01B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 39,430,181 | 9.48% | $2.83B | 2026-08-07 |
| Geode Capital Management, LLC | ▲ Buy | 13,289,622 | 3.19% | $951.79M | 2026-08-12 |
| Wellington Management Group LLP | ▼ Sell | 9,423,895 | 2.27% | $677.20M | 2026-08-14 |
| Morgan Stanley | ▼ Sell | 8,878,849 | 2.13% | $638.03M | 2026-08-13 |
| Janus Henderson Group plc | ▼ Sell | 3,701,747 | 0.89% | $437.57M | 2026-05-18 |
| Northern Trust Corp | ▼ Sell | 5,542,234 | 1.33% | $398.26M | 2026-08-13 |
| Invesco Ltd. | ▲ Buy | 5,523,018 | 1.33% | $396.88M | 2026-08-14 |
| Norges Bank | ▼ Sell | 4,689,847 | 1.13% | $337.01M | 2026-08-12 |
| Bank of America Corp | ▼ Sell | 3,924,926 | 0.94% | $282.05M | 2026-08-14 |
| Goldman Sachs Group Inc | ▼ Sell | 3,199,799 | 0.77% | $229.94M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 3,188,263 | 0.77% | $229.11M | 2026-09-02 |
| JPMorgan Chase & Co | ▼ Sell | 2,624,825 | 0.63% | $192.27M | 2026-08-12 |
| Ruane, Cunniff & Goldfarb L.P. | ▼ Sell | 2,353,300 | 0.57% | $169.11M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 1,813,759 | 0.44% | $130.34M | 2026-08-14 |
| Wells Fargo & Company | ▼ Sell | 1,809,278 | 0.43% | $130.01M | 2026-08-14 |
| Man Group plc | ▲ Buy | 1,805,003 | 0.43% | $129.71M | 2026-08-14 |
| Susquehanna International Group, LLP | ▲ Buy | 1,504,358 | 0.36% | $108.10M | 2026-08-14 |
| Renaissance Technologies LLC | ▲ Buy | 1,403,300 | 0.34% | $100.84M | 2026-08-13 |
| Citigroup Inc | ▲ Buy | 1,265,210 | 0.30% | $90.92M | 2026-08-03 |
| AllianceBernstein L.P. | ▼ Sell | 698,452 | 0.17% | $82.56M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 1,070,929 | 0.26% | $76.96M | 2026-08-14 |
| Capital Research Global Investors | ▼ Sell | 980,811 | 0.24% | $70.48M | 2026-08-12 |
| Neuberger Berman Group LLC | ▼ Sell | 634,661 | 0.15% | $45.61M | 2026-08-13 |
| Squarepoint Ops LLC | ▲ Buy | 633,370 | 0.15% | $45.51M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-09-18 | 2026-10-12 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-07-17 | 2026-09-04 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-06-16 | 2026-07-02 |
| Byron Donalds | House | FL19 | ▲ Buy | $1K - $15K | 2026-06-09 | 2026-07-15 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-04-14 | 2026-05-08 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-03-13 | 2026-04-07 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-02-10 | 2026-03-09 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-12-19 | 2026-01-12 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Rick Larsen | House | WA02 | ▼ Sell | $1K - $15K | 2025-10-06 | 2025-10-16 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-08-05 | 2025-09-12 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-08-04 | 2025-09-12 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-07-22 | 2025-08-13 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-05-15 | 2025-05-31 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-04-17 | 2025-05-08 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-04-28 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-04-07 | 2025-05-08 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-04-01 | 2025-05-14 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-03-05 | 2025-04-11 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-03-03 | 2025-04-14 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-01-15 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2024-12-11 | 2025-08-13 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $15K - $50K | 2024-02-27 | 2024-03-15 |